Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy
about
Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenzaA review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges aheadCan we "hedge" against the development of antiviral resistance among pandemic influenza viruses?Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trialA mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal modelOptimizing treatment regimes to hinder antiviral resistance in influenza across time scalesAntibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance.Virulence attenuation during an influenza A/H5N1 pandemicEffects of influenza antivirals on individual and population immunity over many epidemic waves.The use of mathematical models to inform influenza pandemic preparedness and response.Diagnosis and antiviral intervention strategies for mitigating an influenza epidemic.Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineagesIntervention strategies for an influenza pandemic taking into account secondary bacterial infectionsCombination strategies for pandemic influenza response - a systematic review of mathematical modeling studies.Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1).Infectious disease modeling methods as tools for informing response to novel influenza viruses of unknown pandemic potential.Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpile.Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines.Spatiotemporal dynamics in the early stages of the 2009 A/H1N1 influenza pandemicPredispensing of antivirals to high-risk individuals in an influenza pandemicAntiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the United States.Pre-dispensing of antivirals to high-risk individuals in an influenza pandemic.Analysis of the effectiveness of interventions used during the 2009 A/H1N1 influenza pandemic.Entry screening to delay local transmission of 2009 pandemic influenza A (H1N1).Reconstructing disease outbreaks from genetic data: a graph approach.Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.The impact of case diagnosis coverage and diagnosis delays on the effectiveness of antiviral strategies in mitigating pandemic influenza A/H1N1 2009The GLEaMviz computational tool, a publicly available software to explore realistic epidemic spreading scenarios at the global scale.Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives.Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks.Prioritization of delayed vaccination for pandemic influenza.Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1.The timing and targeting of treatment in influenza pandemics influences the emergence of resistance in structured populations.Pandemic Influenza A H1N1 (2009) Virus: Lessons from the Past and Implications for the Future.Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.A model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homes.Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.How to minimize the attack rate during multiple influenza outbreaks in a heterogeneous population.Timing of antimicrobial use influences the evolution of antimicrobial resistance during disease epidemics.Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies
P2860
Q27437743-48FEB96C-57FA-456E-B87E-A7FBC7C51CF1Q28382972-DEFB591F-DFA7-41DF-85F6-DDC7EA20D6B5Q28475628-227AF0DB-5F84-43BC-B09E-C04597F20938Q28475986-959C79D7-8B27-41C8-9389-C7A9F3D90670Q28477927-61B327D9-A262-479B-A39D-8F94F3034CDBQ28485862-B8C344CC-7036-498A-AAD8-EE9A87C30BBAQ28545750-38178A0D-3F31-4614-A574-E46A27C855F5Q30223401-24F5E5BD-1A70-43A0-9E2F-2DC9307745EEQ30224681-B8A4CB80-231F-4122-A9B0-8D27C94D7E88Q30226500-C764462C-0484-4838-BB32-D764D456F7F3Q30226721-D40DFA0D-74AF-4AE2-8879-9AEA2A090572Q30227284-3782232A-29EA-4137-98B5-75A6F3C720E6Q30227297-D628040F-5BE4-49CD-B384-EB1C85AB6352Q30227388-F5CA3AEE-A697-426E-B2FE-5CC09A15656EQ30227845-B68D0125-BE91-43D3-8E16-8F65623DB636Q30373735-6A5A537F-F10C-4DA7-89B6-DE5DEEAD0FDCQ30379425-E373F8FA-1F85-45FE-A96B-7EBC1240CCBAQ30380700-07240424-163F-4EF9-B937-96EEF4DB30CBQ30383695-CEC122C5-DF1C-488A-A7A8-E22959A5FE84Q30383781-144A3623-B273-443A-A046-28DFE1FFE68AQ30383811-24FAF50B-049A-4440-BE32-B9AB35AECCBBQ30385808-4D92CBC5-6D6D-4791-BD49-310EC3935EB3Q30387348-CCBEECA0-C042-4C6A-B796-B19DD6804B0EQ30387452-B7BA73F3-7C18-4825-99B4-9DAEFA088D92Q30390361-A78A1A6E-08CC-414F-A1C7-C13ED610CAE0Q30395977-38885A5F-7F8B-47DF-8BB7-CDD2672F203AQ30396179-63EBD54F-419F-4F0A-B666-BC74B03BC0ADQ30399263-C74880F7-F4B0-4606-9EBC-65DB7F083FFEQ30400112-DA21A4C6-BB21-4FF7-BE6B-8587129D9511Q30400232-513050E3-4EB1-4EAC-A33D-46F813AC855FQ30400259-207795BC-728B-467D-9A69-2B6799F9EAE0Q30403117-B8D73D55-CDD6-4E8C-B0DF-6511BB082613Q30427202-96A5E331-A54D-4A03-8F77-6F749AE5C20AQ30431394-D0D819CD-BB79-4C47-89F6-D437F8B2AC9BQ33670446-070ACAA1-4D9F-45BE-B072-4D9FA5A23FFAQ33836596-090ADD75-94B3-49A9-AD03-8A24B2FA2ACEQ34120005-32791686-9FBF-4678-9131-24564BD25D4EQ34305125-FB8C798C-71B5-43E0-BDB4-62FBC2BB9E5CQ34580194-CFBA734A-DAB2-4BAF-994D-31330169D6D8Q38633113-20FB0B36-ED8F-4A0F-81D4-3EB24448AF4E
P2860
Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Hedging against antiviral resi ...... of an alternative chemotherapy
@ast
Hedging against antiviral resi ...... of an alternative chemotherapy
@en
Hedging against antiviral resi ...... of an alternative chemotherapy
@nl
type
label
Hedging against antiviral resi ...... of an alternative chemotherapy
@ast
Hedging against antiviral resi ...... of an alternative chemotherapy
@en
Hedging against antiviral resi ...... of an alternative chemotherapy
@nl
prefLabel
Hedging against antiviral resi ...... of an alternative chemotherapy
@ast
Hedging against antiviral resi ...... of an alternative chemotherapy
@en
Hedging against antiviral resi ...... of an alternative chemotherapy
@nl
P2860
P50
P921
P1433
P1476
Hedging against antiviral resi ...... of an alternative chemotherapy
@en
P2860
P304
P356
10.1371/JOURNAL.PMED.1000085
P407
P577
2009-05-19T00:00:00Z